{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:51:22Z","timestamp":1793728282467,"version":"4.6.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Rep."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Prostate-specific membrane antigen positron emission tomography\/computed tomography (PSMA PET\/CT) enables sensitive detection and staging of prostate cancer, yet its relationship with long-term survival remains unclear. This study aimed to assess whether total lesion volume (TLV) measured on [\n                      <jats:sup>18<\/jats:sup>\n                      F]PSMA-1007 PET\/CT predicts overall survival (OS) in prostate cancer patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cohort of 282 patients scanned between 2019 and 2021 was retrospectively studied, including both patients undergoing primary staging and imaging for biochemical recurrence (BCR). Tumour lesions in the prostate\/prostate bed, lymph nodes and bone were manually segmented and TLV was calculated for each compartment and as total of all lesions. Based on TLV, patients were categorized into three groups for each compartment: no detectable tumour, TLV \u2264 median, and TLV\u2009&gt;\u2009median. Bone analyses were dichotomised into any vs. no detectable tumour. The association with OS was assessed using age-adjusted Cox proportional-hazards models and Kaplan\u2013Meier analysis, separately for the primary staging subgroup and the BCR subgroup.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Over a mean follow-up of almost 5\u2009years, 49 patients (17%) died. In the primary staging subgroup (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009171), detectable bone metastases on PSMA PET-CT predicted poorer survival compared to no detectable bone metastasis (HR 2.39,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.031). Among patients with BCR (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009111), total TLV above the median and a prostate TLV above the median both predicted an almost 5 times increased risk of death.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Total lesion volume on [\n                      <jats:sup>18<\/jats:sup>\n                      F]PSMA-1007 PET\/CT was associated with OS, with different prognostic patterns in primary staging and BCR. The results support future incorporation of volumetric PSMA PET metrics into personalized staging and therapeutic decision-making.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41824-026-00292-w","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T23:02:25Z","timestamp":1773356545000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic value of tumour volume based on [18F]PSMA-1007 PET\/CT in prostate cancer"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7372-2598","authenticated-orcid":false,"given":"Jacob","family":"Ingvar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Wittgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vigdis","family":"Sverrisdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin","family":"Tr\u00e4g\u00e5rdh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Bjartell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"5","key":"292_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","volume":"24","author":"G Attard","year":"2023","unstructured":"Attard G, Murphy L, Clarke NW, Sachdeva A, Jones C, Hoyle A et al (2023) Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. Lancet Oncol 24(5):443\u2013456","journal-title":"The Lancet Oncol"},{"issue":"3","key":"292_CR2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.eururo.2015.06.010","volume":"69","author":"L Budaus","year":"2016","unstructured":"Budaus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H et al (2016) Initial experience of (68)Ga-PSMA PET\/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 69(3):393\u2013396","journal-title":"Eur Urol"},{"issue":"6 Pt 1","key":"292_CR3","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1097\/01.ju.0000143448.04161.cc","volume":"172","author":"S Daneshmand","year":"2004","unstructured":"Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J et al (2004) Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 172(6 Pt 1):2252\u20132255","journal-title":"J Urol"},{"issue":"3","key":"292_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M et al (2018) Prostate cancer Molecular imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-Ligand PET\/CT. J Nucl Med 59(3):469\u2013478","journal-title":"J Nucl Med"},{"key":"292_CR5","doi-asserted-by":"crossref","unstructured":"Emmett L, Papa N, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM et al (2025) Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol","DOI":"10.1016\/S1470-2045(25)00339-0"},{"issue":"24","key":"292_CR6","doi-asserted-by":"publisher","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","volume":"25","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J et al (2019) Prostate-specific membrane antigen ligand positron Emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res 25(24):7448\u20137454","journal-title":"Clin Cancer Res"},{"issue":"12","key":"292_CR7","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/pros.23645","volume":"78","author":"E Francini","year":"2018","unstructured":"Francini E, Gray KP, Xie W, Shaw GK, Valenca L, Bernard B et al (2018) Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate 78(12):889\u2013895","journal-title":"Prostate"},{"issue":"11","key":"292_CR8","first-page":"1651","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR et al (2022) Novel framework for treatment Response Evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an International multicenter study. J Nucl Med 63(11):1651\u20131658","journal-title":"J Nucl Med"},{"issue":"2","key":"292_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","volume":"68","author":"G Gandaglia","year":"2015","unstructured":"Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V et al (2015) Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol 68(2):325\u2013334","journal-title":"Eur Urol"},{"key":"292_CR10","unstructured":"Herrmann K, Walz J, MacLennan S, Briganti A, Cornford P, Czernin J et al (2025) SPARC: the standardised prostate-specific membrane antigen positron emission tomography\/computed tomography analysis and reporting consensus: a Delphi analysis. Eur Urol"},{"issue":"10231","key":"292_CR11","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395(10231):1208\u20131216","journal-title":"Lancet"},{"issue":"9","key":"292_CR12","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","volume":"25","author":"MJ Karpinski","year":"2024","unstructured":"Karpinski MJ, Husing J, Claassen K, Moller L, Kajuter H, Oesterling F et al (2024) Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. The Lancet Oncol 25(9):1188\u20131201","journal-title":"The Lancet Oncol"},{"key":"292_CR13","doi-asserted-by":"crossref","unstructured":"Karpinski MJ, Rahbar K, Bogemann M, Nikoukar LR, Schafers M, Hoberuck S et al (2025) Updated prostate cancer risk groups by prostate-specific membrane antigen Positron Emission tomography prostate cancer Molecular imaging Standardized Evaluation (PPP2): results from an International multicentre Registry study. Eur Urol","DOI":"10.1016\/j.eururo.2025.06.006"},{"issue":"11","key":"292_CR14","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM et al (2018) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 36(11):1080\u20131087","journal-title":"J Clin Oncol"},{"issue":"1","key":"292_CR15","doi-asserted-by":"publisher","first-page":"9104","DOI":"10.1038\/s41598-020-64073-6","volume":"10","author":"D Liu","year":"2020","unstructured":"Liu D, Kuai Y, Zhu R, Zhou C, Tao Y, Han W et al (2020) Prognosis of prostate cancer and bone metastasis pattern of patients: a SEER-based study and a local hospital based study from China. Sci Rep 10(1):9104","journal-title":"Sci Rep"},{"issue":"6","key":"292_CR16","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.eururo.2025.03.003","volume":"87","author":"E Mazzone","year":"2025","unstructured":"Mazzone E, Cannoletta D, Quarta L, Chen DC, Thomson A, Barletta F et al (2025) A comprehensive systematic review and meta-analysis of the role of prostate-specific membrane antigen positron emission tomography for prostate cancer diagnosis and primary staging before definitive treatment. Eur Urol 87(6):654\u2013671","journal-title":"Eur Urol"},{"key":"292_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fsurg.2016.00065","volume":"3","author":"L Moris","year":"2016","unstructured":"Moris L, Van den Broeck T, Tosco L, Van Baelen A, Gontero P, Karnes RJ et al (2016) Impact of lymph node burden on survival of high-risk prostate cancer patients following radical prostatectomy and pelvic lymph node dissection. Front Surg 3:65","journal-title":"Front Surg"},{"key":"292_CR18","doi-asserted-by":"crossref","unstructured":"Rosenzweig B, Haramaty R, Davidson T, Lazarovich A, Shvero A, Haifler M et al (2022) Very low prostate PET\/CT PSMA uptake May Be misleading in staging Radical Prostatectomy candidates. J Pers Med 12(3)","DOI":"10.3390\/jpm12030410"},{"issue":"5","key":"292_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J et al (2023) Second version of the prostate cancer Molecular imaging Standardized Evaluation framework including Response Evaluation for clinical trials (PROMISE V2). Eur Urol 83(5):405\u2013412","journal-title":"Eur Urol"},{"issue":"4","key":"292_CR20","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","volume":"48","author":"R Seifert","year":"2021","unstructured":"Seifert R, Kessel K, Schlack K, Weber M, Herrmann K, Spanke M et al (2021) PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [(177)Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imag 48(4):1200\u20131210","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"5","key":"292_CR21","doi-asserted-by":"publisher","first-page":"738","DOI":"10.2967\/jnumed.118.215434","volume":"64","author":"R Seifert","year":"2023","unstructured":"Seifert R, Telli T, Opitz M, Barbato F, Berliner C, Nader M et al (2023) Unspecific (18)F-PSMA-1007 bone uptake evaluated through PSMA-11 PET, bone scanning, and MRI triple validation in patients with biochemical recurrence of prostate cancer. J Nucl Med 64(5):738\u2013743","journal-title":"J Nucl Med"},{"issue":"4","key":"292_CR22","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/cas.14722","volume":"112","author":"M Shiota","year":"2021","unstructured":"Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T et al (2021) Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients. Cancer Sci 112(4):1524\u20131533","journal-title":"Cancer Sci"},{"issue":"9","key":"292_CR23","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1007\/s00259-025-07198-y","volume":"52","author":"T Telli","year":"2025","unstructured":"Telli T, Lopes L, Karpinski M, Pabst KM, Grunwald V, Shi K et al (2025) Prognostic value of [(18)F]FDG- and PSMA-PET in patients evaluated for [(177)Lu]Lu-PSMA therapy of mCRPC. Eur J Nucl Med Mol Imag 52(9):3199\u20133210","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1","key":"292_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40658-020-00316-9","volume":"7","author":"E Tragardh","year":"2020","unstructured":"Tragardh E, Borrelli P, Kaboteh R, Gillberg T, Ulen J, Enqvist O et al (2020) RECOMIA-a cloud-based platform for artificial intelligence research in nuclear medicine and radiology. EJNMMI Phys 7(1):51","journal-title":"EJNMMI Phys"}],"container-title":["EJNMMI Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-026-00292-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41824-026-00292-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-026-00292-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:15:47Z","timestamp":1781637347000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41824-026-00292-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["292"],"URL":"https:\/\/doi.org\/10.1186\/s41824-026-00292-w","relation":{},"ISSN":["3005-074X"],"issn-type":[{"value":"3005-074X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Regional Ethics Committee in Lund (2016\/417, 2018\/117, 2018\/753, 2020\u201302524) and all patients signed an informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No financial interest or benefit related to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}